Holding(s) in Company
Summary by AI BETAClose X
TR-1: Standard form for notification of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i | ||||||
|
| ||||||
|
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: |
NIOX Group PLC | |||||
|
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | ||||||
|
Non-UK issuer |
| |||||
|
2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | ||||||
|
An acquisition or disposal of voting rights |
| |||||
|
An acquisition or disposal of financial instruments |
| |||||
|
An event changing the breakdown of voting rights |
| |||||
|
Other (please specify) iii: A change in the Issuer’s total voting rights following the conclusion of the Issuer’s tender offer notified by the Issuer on 22 October 2026. |
X | |||||
|
3. Details of person subject to the notification obligation iv | ||||||
|
Name |
AstraZeneca PLC | |||||
|
City and country of registered office (if applicable) |
Cambridge, England | |||||
|
4. Full name of shareholder(s) (if different from 3.) v | ||||||
|
Name |
AstraZeneca UK Limited | |||||
|
City and country of registered office (if applicable) |
Cambridge, England | |||||
|
5. Date on which the threshold was crossed or reached vi: |
22 October 2026 | |||||
|
6. Date on which issuer notified (DD/MM/YYYY): |
22 October 2026 | |||||
|
7. Total positions of person(s) subject to the notification obligation | ||||||
|
|
% of voting rights attached to shares (total of 8. A) |
% of voting rights through financial instruments |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer (8.A + 8.B) vii | ||
|
Resulting situation on the date on which threshold was crossed or reached |
16.31% |
|
16.31% |
66,093,108 | ||
|
Position of previous notification (if applicable) |
15.86% |
|
|
| ||
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii | |||||||||
|
A: Voting rights attached to shares | |||||||||
|
Class/type of ISIN code (if possible) |
Number of voting rights ix |
% of voting rights | |||||||
|
Direct (DTR5.1) |
Indirect (DTR5.2.1) |
Direct (DTR5.1) |
Indirect (DTR5.2.1) | ||||||
|
Ordinary shares of 0.08 pence GB00BJVD3B28 |
|
66,093,108 |
|
16.31% | |||||
|
|
|
|
|
| |||||
|
|
|
|
|
| |||||
|
SUBTOTAL 8. A |
66,093,108 |
16.31% | |||||||
|
| |||||||||
|
B 1: Financial Instruments according to DTR5.3.1R (1) (a) | |||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights | |||||
|
|
|
|
|
| |||||
|
|
|
|
|
| |||||
|
|
|
|
|
| |||||
|
|
|
SUBTOTAL 8. B 1 |
|
| |||||
|
| |||||||||
|
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) | |||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Physical or cash Settlement xii |
Number of voting rights |
% of voting rights | ||||
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
| ||||
|
|
|
|
SUBTOTAL 8.B.2 |
|
| ||||
|
| |||||||||
|
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) | ||||
|
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii |
| |||
|
Full chain of controlled undertakings through which the voting rights and/or the |
X | |||
|
Name xv |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold | |
|
AstraZeneca PLC |
16.31% |
|
16.31% | |
|
AstraZeneca Intermediate Holdings Limited |
16.31% |
|
16.31% | |
|
AstraZeneca UK Limited |
16.31% |
|
16.31% | |
|
|
|
|
| |
|
|
|
|
| |
|
| ||||
|
10. In case of proxy voting, please identify: | ||||
|
Name of the proxy holder |
| |||
|
The number and % of voting rights held |
| |||
|
The date until which the voting rights will be held |
| |||
|
| ||||
|
11. Additional information xvi | ||||
|
| ||||
|
Place of completion |
Cambridge, England |
|
Date of completion |
26 October 2026 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 9 hours ago Johnson Matthey
- 11 hours ago Galliford Try
- 11 hours ago Galliford Try
- 11 hours ago Centrica
- 11 hours ago Smith & Nephew